[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)]

MeSH terms

• Anti-Arrhythmia Agents / therapeutic use
• Anticoagulants / therapeutic use
• Atrial Fibrillation / complications
• Atrial Fibrillation / drug therapy*
• Digoxin / therapeutic use*
• Embolism / etiology
• Embolism / prevention & control
• Factor Xa Inhibitors / administration & dosage*
• Factor Xa Inhibitors / therapeutic use
• Humans
• Retrospective Studies
• Rivaroxaban / administration & dosage*
• Rivaroxaban / therapeutic use
• Stroke / etiology
• Stroke / prevention & control
• Vitamin K / antagonists & inhibitors